ISSN: 2578-4838
Authors: Zhu G*
Objective: Anemia is clinical common event. There are many types of anemias, which included stem cell problems, vitamin deficiency, chronic diseases and drug antibody-induced immune hemolytic anemia. In this study, a retrospective purpose was investigated to assess the clinical efficacy of treatment and their outcome. Methods: 40 patients with different types of anemias were presented during 1989-2019. The therapeutical design among those patients with anemias was setted to the various regimen according to diseases diagnoses. Results and conclusion: 23 patients achieved cure or complete remission (CR), with the exception of refractory cancers and uremic anemia. Iron supplement was provided in 5 iron deficiency anemia. One megaloblastic anemia produced an excellent response following the supplement of vitamin B12 and folic acid. 2 aplastic anemia obtained complete remission (CR) with the integrated protocol of methyltestosterone,adenine, leucogen,and levamisol. Steroid hormone(e.g. prednisone) mixed traditional medicine were occasionally promising benefit in a nephrotic syndrome and renal insufficiency. Among 2 cases with drug-induced immune hemolytic anemia (DIIHA), laboratory studies one patient’s serum contained paracetamol-dependent antibody that in the presence of paracetamol, agglutinated in vitro with “O†red cells with or without complement. Drug antibody titer was 1:4 positive. The immune hemolysis was mediated via both immune complex and drug-adsorption, while another herba origanum vulgare- induced hemolysis secondary to drug adsorption only. In addition, as to anemia caused by malignant tumours, the molecular genetic regulation of retinoic acid in acute promyelocytic leukemia (APL) has been further illustrated (see figure in full text). Therefore, to strengthen the active prevention and/or early interceptive treatment of anemia is our care.
Keywords: Anemia Iron; vitamin B12 and folic acid; Drug induced immune hemolytic anemia (DIIHA); Prevention and treatment
